BREAKING NEWS! They Finally Changed the Name. Here’s Why It Changes Everything.
PCOS is now PMOS — and as a physician who has cared for these patients for 25 years, I can tell you this is far more than a semantic shift.
THE METABOLIC FIX | Substack | May 12, 2026
By Dr. Herman Weiss, MD, MBA, FACOG
Today, published in The Lancet and presented simultaneously at the European Congress of Endocrinology in Prague, a landmark global consensus paper made official what many of us in women’s metabolic health have been saying for years: the name “polycystic ovary syndrome” is wrong. It has always been wrong. And now — after 11 years, 22,000 voices from 56 leading academic, clinical, and patient organizations across the globe — the medical world has finally caught up.
PCOS is dead. Long live PMOS.
Polyendocrine Metabolic Ovarian Syndrome. That’s the new name. One letter changed in the acronym. An enormous paradigm shifted in medicine.
I want to take you inside why this matters — not just as a news item, but as one of the most consequential reframings in women’s health in a generation. Because how we name a disease determines how we see it, how we treat it, who studies it, who funds it, and ultimately, how well our patients do.
First, Some History: Why PCOS Was Always the Wrong Name
The term “polycystic ovary syndrome” was coined in the 1930s by Stein and Leventhal, based on the observation of enlarged, cyst-containing ovaries in women with menstrual irregularities and excess androgens. At the time, naming it for the most visually prominent finding — the ovaries — was understandable. It was the era before sophisticated hormonal assays, before metabolic phenotyping, before we understood insulin’s role in androgen excess. We named what we could see.
The problem? The name stuck. For nearly 90 years, medicine anchored one of the most common endocrine disorders in women to a finding that is neither universal nor central to the disease.
Here is what the name PCOS implied to every clinician, every patient, every researcher, every insurance underwriter, and every NIH grant reviewer who encountered it:
• It’s an ovarian problem.
• It involves cysts.
• It belongs to gynecology.
• It’s primarily about reproduction.
Every single one of those implications is wrong — or at minimum, profoundly incomplete.
What the Name Got Wrong (Clinically and Mechanistically)
Let’s be precise about the pathophysiology, because the new name, PMOS — Polyendocrine Metabolic Ovarian Syndrome — earns each of its words.
Polyendocrine.
This is not a single-hormone disorder. PMOS involves dysregulation across multiple endocrine axes simultaneously: hypothalamic-pituitary-ovarian axis dysfunction, hyperandrogenism, insulin resistance with compensatory hyperinsulinemia, altered GnRH pulsatility, disrupted LH/FSH ratios, cortisol dysregulation under stress, and emerging evidence of thyroid co-involvement. The word “polycystic” captured none of this. The word “polyendocrine” captures all of it.
Metabolic.
This is perhaps the most important word added. Insulin resistance is present in 70–80% of women with PMOS, regardless of body weight. The metabolic consequences — type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, hypertension, and elevated cardiovascular risk — are not complications of PMOS. They are features of it. They were hiding in plain sight behind an ovary-focused name that directed clinicians toward reproductive medicine and away from metabolic medicine.
Ovarian.
The ovaries remain in the name, appropriately. Ovarian dysfunction — disrupted folliculogenesis, arrested follicular development, androgen hypersecretion from theca cells — is a real and central component of this syndrome. But notice the shift: the ovaries are one part of a larger picture, not the headline.
What This Name Change Means for Patients
1. Fewer Missed Diagnoses
The single most common complaint I hear from women with PMOS is some version of this: “I went to three doctors before anyone took me seriously.” Or: “My ultrasound was normal, so they said I didn’t have PCOS.” This happened because the name trained clinicians to look for the wrong thing. PMOS recenters the diagnostic lens on the endocrine and metabolic features that are actually universal. This alone could accelerate diagnosis for millions of women who currently wait an average of 2 years to receive a correct diagnosis.
2. Reduced Stigma
The original name carried a brutal double burden. First, it anchored the disorder in reproduction — framing every woman with PMOS primarily through the lens of her fertility. Second, because the metabolic features drive weight gain and the condition disproportionately affects heavier women, “PCOS” became entangled with weight stigma and self-blame. Women were told: “Just lose weight and it will go away.” The name gave that dismissal intellectual cover. PMOS doesn’t. PMOS says: this is a polyendocrine disorder. The metabolic dysfunction came first.
3. Broader, More Holistic Treatment
When gynecology “owned” PCOS, the therapeutic toolkit was reproductive: oral contraceptives, clomiphene, metformin as an afterthought. PMOS, by naming the endocrine and metabolic nature of the disease, invites endocrinology, cardiology, hepatology, and metabolic medicine to the table as equal partners. It creates the clinical permission — and eventually the guideline mandate — for comprehensive metabolic screening: fasting insulin and glucose, lipid panels, hepatic function, blood pressure, sleep apnea evaluation, and psychological health assessment. These are the interventions that protect women with PMOS from their most serious long-term risks.
What This Name Change Means for Research
A disease’s name is not just a label. It is a filing system for the entire apparatus of medical science. It determines which journals publish the research, which subspecialties generate the investigators, which NIH study sections review the grants, and which ICD codes are used for billing and epidemiological tracking.
PMOS changes the filing system. Consider:
• Grant funding: NIH study sections for endocrinology and metabolism have significantly larger budgets and broader scope than reproductive medicine sections. PMOS now has a credible claim on those resources — and on cardiovascular disease, diabetes, and metabolic syndrome research portfolios.
• Industry investment: GLP-1 receptor agonists, SGLT-2 inhibitors, and novel insulin sensitizers are among the most commercially active drug classes in medicine right now. PMOS, explicitly named as a metabolic syndrome, positions itself as a legitimate indication for these agents — opening a pipeline the old PCOS framing kept partially closed.
• International disease classification: The Lancet paper makes explicit that ICD codes and disease classification systems will be updated. This is monumental. ICD codes drive insurance coverage, hospital coding, and population-level epidemiology. A reclassification from a gynecological code toward an endocrine/metabolic code reshapes decades of data and aligns future collection with biological reality.
• Clinical trials: The populations enrolled in trials are defined by diagnosis codes and inclusion criteria. Broadening the framing of PMOS will expand trial eligibility, improve phenotypic characterization, and produce data that is more actionable across the full metabolic spectrum.
What This Name Change Means for Education
Medical education is downstream of nomenclature. When the textbook chapter is titled “Polycystic Ovary Syndrome” and filed under gynecology, medical students learn to look for it in OB/GYN rotations, not on internal medicine wards. Primary care physicians learn it as something to refer out, not manage longitudinally.
PMOS repositions this disease as a core competency of metabolic medicine — something every internist, every family physician, every endocrinologist, every cardiologist, and yes, every OB/GYN should be trained to recognize and manage. The curricular implications ripple through medical schools, residency programs, CME, and board examination content.
There is also the patient education dimension. Women with PMOS have historically received deeply fragmented information — some from their gynecologist about fertility, some from their PCP about weight, some from the internet about “natural cures.” A coherent name — one that accurately describes the condition — is the beginning of coherent health literacy.
What This Means for Women’s Metabolic Health — and ProvationLife
At ProvationLife, we built our entire clinical philosophy on exactly this premise: that women’s metabolic health disorders are polyendocrine, gut-mediated, inflammation-driven, systemic conditions that require an integrated, multisystem approach. We called it before the Lancet did.
The PMOS renaming is intellectual validation — and a commercial inflection point. Here’s what I see coming:
• The patient population just got larger on paper. Women who never identified with “ovarian” or “cysts” but do identify with insulin resistance, metabolic dysfunction, and hormonal chaos will now recognize themselves in the diagnosis. Prevalence estimates — currently at 1 in 8 women globally, 170+ million people — may rise.
• The supplement, nutrition, and lifestyle market will follow. Products and programs targeting PMOS metabolic features — gut microbiome optimization (the estrobolome!), insulin sensitization, androgen modulation, anti-inflammatory nutrition — now have a more scientifically credible umbrella under which to operate.
• Payers and health systems will need to adapt. As clinical guidelines are updated to reflect PMOS’s metabolic scope, insurance coverage for metabolic screening, CGM use, and GLP-1 therapies in this population will face pressure to expand.
• The mainstream media conversation accelerates. The reframing of one of the most common women’s health conditions as a metabolic syndrome — not a reproductive one — aligns exactly with the broader cultural conversation about women’s health and the failures of a system that has historically reduced women to their reproductive organs.
The Dissenting Voice: Why This Isn’t Universally Celebrated
Science requires intellectual honesty, and I want to acknowledge the legitimate criticism. PCOS Challenge — one of the most prominent patient advocacy organizations — issued a statement today expressing concern that the renaming process, while well-intentioned, did not establish the evidentiary standard required to prove that the name itself caused the documented harms, or that a new name will correct them.
They are not wrong about this. A name change is necessary but not sufficient. The hard work of structural reform — in medical education, in reimbursement, in research funding, in guideline development — remains.
But I would argue: you cannot have the institutional reform without the name change. The name is the frame. Get the frame right first.
The Bottom Line: What Took So Long?
Fourteen years. More than 22,000 stakeholders. Modified Delphi methods. Nominal group technique workshops. International surveys across six continents. A paper in The Lancet.
Why did it take this long to rename a disease that has been incorrectly named since the 1930s? The answer tells you everything you need to know about medicine’s relationship with women’s health. When a condition is filed under “women’s reproductive problems,” it exists in a second-tier research and policy environment — underfunded relative to its prevalence, under-represented in trial design, and underestimated in its systemic impact.
The name PCOS wasn’t just inaccurate. It was a permission structure for neglect.
PMOS is a correction. It is medicine acknowledging, in its most formal possible language — a global consensus paper in The Lancet — that it got the framing wrong, and that the women who suffered delayed diagnoses, fragmented care, dismissed symptoms, and misunderstood metabolic risk deserved better.
They still do. But at least now, the name tells the truth.
Dr. Herman Weiss, MD, MBA, FACOG
Board-certified OB/GYN • 25 years of clinical experience • CEO/Founder, ProvationLife™
@hweissmd | The Metabolic Fix | ProvationLife.com
Sources
• Teede HJ et al. “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.” The Lancet, May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8
• University of Colorado Anschutz Medical Campus press release, May 12, 2026
• PCOS Challenge: The National PCOS Association statement, May 12, 2026
• eClinicalMedicine / The Lancet: “Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming,” 2025
• STAT News: “PCOS is now called PMOS. The renaming process lasted a decade,” May 12, 2026
• Live Science: “Goodbye PCOS: Polycystic ovary syndrome is getting a new name,” May 12, 2026
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.